WO2023158411A1 - A tablet of tolvaptan and at least one binder processed with wet granulation - Google Patents

A tablet of tolvaptan and at least one binder processed with wet granulation Download PDF

Info

Publication number
WO2023158411A1
WO2023158411A1 PCT/TR2023/050146 TR2023050146W WO2023158411A1 WO 2023158411 A1 WO2023158411 A1 WO 2023158411A1 TR 2023050146 W TR2023050146 W TR 2023050146W WO 2023158411 A1 WO2023158411 A1 WO 2023158411A1
Authority
WO
WIPO (PCT)
Prior art keywords
sodium
tablet according
cellulose
tolvaptan
tablet
Prior art date
Application number
PCT/TR2023/050146
Other languages
French (fr)
Inventor
Fatih Sunel
Nur PEHLIVAN AKALIN
Aydan OZDEN
Furkan KIVANC
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2023158411A1 publication Critical patent/WO2023158411A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a tablet comprising an intragranular composition comprising amorphous tolvaptan and at least one binder, wherein the intragranular composition is obtained by wet-granulation using water.
  • Tolvaptan is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia.
  • V2 arginine vasopressin receptor 2
  • tolvaptan selectively and competitively binds to and blocks the V2 receptor located in the walls of the vasculature and luminal membranes of renal collecting ducts, thereby preventing the binding of vasopressin to the V2 receptor. This prevents water absorption in the kidneys and increases the excretion of electrolyte- free water via the kidneys. This reduces intravascular volume and increases serum sodium concentrations and osmolality.
  • Tolvaptan is chemically described as N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-lH- benzo[b]azepine-l-carbonyl)-3-methylphenyl)-2-methylbenzamide. Its empirical formula is
  • Tolvaptan is available as oral tablets containing 15 mg and 30 mg of tolvaptan, with trade name SAMSCA® by Otsuka America Pharmaceutical for the treatment of clinically significant hypervolemic and euvolemic hyponatremia.
  • Tolvaptan is a class IV drug in the BCS classification, that is, a low-soluble and hypotonic drug.
  • BCS BCS classification
  • dissolution is the rate-limiting process of absorption, and is often the most important factor affecting its bioavailability.
  • U.S. Pat. No. 5,258,510 disclose tolvaptan.
  • CN102366412 discloses a preparation method of a tolvaptan tablet. The method is wet granulation without water.
  • WO2008156217 discloses a pharmaceutical solid preparation comprising tolvaptan and hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50 wt.% or greater. Also, a method for preparing the pharmaceutical solid preparation discloses. The method is wet or dry granulation.
  • the main object of the present invention is to provide a tablet comprising amorphous tolvaptan with having desired level of dissolution rate and high stability and excellent pharmacomechanic properties, such as flowability, compressibility and content uniformity which overcomes the abovedescribed problems in the prior art and have additive advantages over them.
  • Another object of the present invention is to provides a process for a tablet composition comprising tolvaptan or crystalline polymorph thereof.
  • the process is a simple, rapid, cost effective, time-saving and industrially convenient method.
  • Tolvaptan is poorly soluble in water. This causes problems of dissolution profile and bioavailability. In the present invention, some studies have been done so that these problems do not appear.
  • Tolvaptan Amorphous is better solubility than Tolvaptan Crystalline.
  • stability is also very important. It is very important for its stability that amorphous tolvaptan can be produced without turning into crystals and that it remains amorphous throughout its shelf life. To achieve this, it is found that for a tablet comprising amorphous tolvaptan, using wet granulation method with water is used and both the desired dissolution profile and stability is achieved.
  • the term "intragranular composition” refers to a population of granules that are wetted with solvent and then dried and granulated. Intragranular composition can be called also “granulate” or “granulate component”.
  • the "extragranular composition” refers is the part that does not participate in wet granulation.
  • a tablet comprises an intragranular composition comprising amorphous tolvaptan and at least one binder, wherein the intragranular composition obtained by wet-granulation using water.
  • tolvaptan is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug. In this invention, to eliminate this problem, wet granulation is preferred in terms of pharmacotechnical properties, such as flowability, compressibility and content uniformity of tolvaptan.
  • Suitable binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, starch, pregelatinized starch, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, polymethacrylates, methacrylate polymers, hyaluronic acid, pectin, polysaccharides, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
  • the viscosity of a binder is a measure of its flow characteristics, and the performance of a bituminous mix is greatly affected by its viscosity.
  • binders having low viscosity are used.
  • the binder is polyvinylpyrrolidone.
  • Polymer having low viscosity is povidone with a dynamic viscosity of 10% aqueous solution at 25°C up to about 10 mPa.s.
  • Povidone is selected from the consisting of K12, K17, K25,K30, VA 64 and mixture thereof, more preferably VA 64.
  • the amount of binder is between 1.0% and 20.0%, between 1.0% and 15.0% by weight of the total composition.
  • the amount of binder is between 3.0% and 10.0% by weight of the total composition.
  • the amount of amorphous tolvaptan is between 5.0% and 25.0%, between 8.0% and 25.0%, between 10.0% and 20.0% by weight of the total composition.
  • amorphous tolvaptan having the following particle sizes is important for formulation. Too small particle sizes influence the manufacturability, for example by sticking or filming. On the other hand too large particles negatively affect the dissolution properties of the pharmaceutical composition and dosage form and thus the bioavailability. In the following preferred ranges of the particle size distribution are described.
  • particle size distribution is defined by the cumulative volume size distribution as tested by a conventionally accepted method which is the laser diffraction method determined by the equipment of Malvern Mastersizer 2000 laser diffraction particle size analyzer analyzer.
  • D (0.9)” or “d90” means that the size at which %90 by volume of the particles are finer
  • d (0.1) means that the size at which 10% by volume of the particles are finer
  • d (0.5) means that the size at which 50% by volume of the particles are finer.
  • particle size distribution of d (0.9) or d (0.5) or D(0.1) value of tolvaptan has been measured with solid samples and these values have been identified by Malvern Mastersizer 2000 laser diffraction particle size analyzer.
  • amorphous tolvaptan has a d (0.9) particle size between 2 pm and 100 pm or between 3 pm and 50 pm or between 3 pm and 30 pm.
  • amorphous tolvaptan has a d (0.9) particle size between 3 pm and 30 pm or between 3 pm and 25 pm or between 3 pm and 20 pm.
  • amorphous tolvaptan has a d (0.5) particle size between 1 pm and 25 pm or between 1 pm and 15 pm or between 1 pm and 8 pm.
  • amorphous tolvaptan has a d (0.5) particle size between 1 pm and 5 pm. According to this embodiment of the present invention, amorphous tolvaptan has a d (0.1) particle size between 0.1 pm and 20 pm or between 0.1 pm and 12 pm or between 0.1 pm and 8 pm.
  • amorphous tolvaptan has a d (0.9) particle size between 2 pm and 100 pm
  • amorphous tolvaptan has a d (0.5) particle size between 1 pm and 30 pm
  • amorphous tolvaptan has a d (0.1) particle size between 0.1 pm and 12 pm.
  • a tablet comprises an intragranular composition comprising amorphous tolvaptan having a d (0.9) particle size between 2 pm and 100 pm and polyvinylpyrrolidone, wherein the intragranular composition is obtained by wet-granulation using water.
  • an intragranular composition further comprises at least one pharmaceutically acceptable excipient selected from the group comprising disintegrants, fillers or mixtures thereof.
  • Suitable disintegrants are selected from the group comprising croscarmellose sodium, corn starch, starch, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, hydroxymethyl starch or mixtures thereof.
  • the disintegrant is croscarmellose sodium.
  • the amount of disintegrant is between 1.0% and 20.0%, preferably between 3.0% and 15.0%, more preferably between 3.0% and 10.0% by weight of the total composition.
  • Suitable fillers are selected from the group comprising microcrystalline cellulose, lactose monohydrate, ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, compressible sugar, ethylcellulose, fructose, glyceryl palmitostearate, lactitol, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, sorbitol, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, xylitol or mixtures thereof.
  • the filler is microcrystalline cellulose or lactose monohydrate or mixtures thereof. According to one embodiment of this invention, the amount of filler is between 55.0% and 90.0%, between 60.0% and 80.0% by weight of the total composition.
  • the tablet further comprises an extragranular composition comprising at least one pharmaceutically acceptable excipient selected from the group comprising coloring agents, lubricants or mixtures thereof.
  • Suitable coloring agents are selected from the group comprising indigo carmin aliminium lake, ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Drug & Cosmetic
  • the coloring agent is indigo carmin aliminium lake.
  • This excipient is known as redox indicator. It prevents the active substance from being degraded by giving its own reversible reaction against oxidative and reducing substances (stress factors). Since the reaction is reversible, it is not completely depleted by its own degradation, and the raw material is protected from stress factors (oxidative and reducing species). This contributes positively to the shelf life of the product.
  • This coloring agent provides the desired stability.
  • the tablet comprises;
  • Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, sodium stearyl fumarate, potassium stearate, stearic acid, sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols or mixtures thereof.
  • the lubricant is magnesium stearate.
  • a process for preparing a tablet comprises the following steps: a) Dissolving polyvinylpyrrolidone VA 64 in water, b) Mixing amorphous tolvaptan, at least one disintegrant and at least one filler, c) Granulating the dry mixture at step (b) with the mixture step (a) and obtained wet granule, d) Drying the wet granule and then sieving, e) Adding indigo carmin aliminium lake and then mixing, f) Adding at least one lubricant and then mixing, g) Compressing the mixture into tablets.
  • a process for preparing a tablet comprises the following steps: a) Dissolving polyvinylpyrrolidone VA 64 in water, b) Mixing amorphous tolvaptan, lactose monohydrate, croscarmellose sodium and microcystralline cellulose, c) Granulating the dry mixture at step (b) with the mixture step (a) and obtained wet granule, d) Drying the wet granule and then sieving, e) Adding indigo carmin aliminium lake and then mixing, f) Adding magnesium stearate and then mixing, g) Compressing the mixture into tablets.
  • Example 1 Example 2:
  • a process for example 1 or 2 a) Dissolving polyvinylpyrrolidone VA 64 in water, b) Mixing amorphous tolvaptan, lactose monohydrate, croscarmellose sodium and microcystralline cellulose, c) Granulating the dry mixture at step (b) with the mixture step (a) and obtained wet granule, d) Drying the wet granule and then sieving, e) Adding indigo carmin aliminium lake and then mixing, f) Adding magnesium stearate and then mixing, g) Compressing the mixture into tablets.

Abstract

The present invention relates to a tablet comprising an intragranular composition comprising amorphous tolvaptan and at least one binder, wherein the intragranular composition is obtained by wet-granulation using water.

Description

A TABLET OF TOLVAPTAN AND AT LEAST ONE BINDER PROCESSED WITH WET GRANULATION
Field of the Invention
The present invention relates to a tablet comprising an intragranular composition comprising amorphous tolvaptan and at least one binder, wherein the intragranular composition is obtained by wet-granulation using water.
Background of the Invention
Tolvaptan is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia. Upon oral administration, tolvaptan selectively and competitively binds to and blocks the V2 receptor located in the walls of the vasculature and luminal membranes of renal collecting ducts, thereby preventing the binding of vasopressin to the V2 receptor. This prevents water absorption in the kidneys and increases the excretion of electrolyte- free water via the kidneys. This reduces intravascular volume and increases serum sodium concentrations and osmolality.
Tolvaptan is chemically described as N-(4-(7-Chloro-5-hydroxy-2,3,4,5-tetrahydro-lH- benzo[b]azepine-l-carbonyl)-3-methylphenyl)-2-methylbenzamide. Its empirical formula is
C26H25CIN2O3, with structural formula as follows:
Figure imgf000002_0001
Tolvaptan is available as oral tablets containing 15 mg and 30 mg of tolvaptan, with trade name SAMSCA® by Otsuka America Pharmaceutical for the treatment of clinically significant hypervolemic and euvolemic hyponatremia.
Tolvaptan is a class IV drug in the BCS classification, that is, a low-soluble and hypotonic drug. For poorly soluble drugs, its dissolution is the rate-limiting process of absorption, and is often the most important factor affecting its bioavailability. U.S. Pat. No. 5,258,510 disclose tolvaptan.
CN102366412 (A) discloses a preparation method of a tolvaptan tablet. The method is wet granulation without water.
WO2008156217 (A2) discloses a pharmaceutical solid preparation comprising tolvaptan and hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50 wt.% or greater. Also, a method for preparing the pharmaceutical solid preparation discloses. The method is wet or dry granulation.
In prior art, there are also several patents which disclose tolvaptan in oral pharmaceutical dosage forms. However, despite the dissolution problem of tolvaptan, an effective formulation and method has not been disclosed.
There still remains a need in the art to provide an improved a tablet comprising tolvaptan having high solubility, excellent pharmacomechanic properties and accordingly a high bioavailability and a long-term stability which is also obtained by using wet granulation.
Detailed Description of the Invention
The main object of the present invention is to provide a tablet comprising amorphous tolvaptan with having desired level of dissolution rate and high stability and excellent pharmacomechanic properties, such as flowability, compressibility and content uniformity which overcomes the abovedescribed problems in the prior art and have additive advantages over them.
Another object of the present invention is to provides a process for a tablet composition comprising tolvaptan or crystalline polymorph thereof. The process is a simple, rapid, cost effective, time-saving and industrially convenient method.
Tolvaptan is poorly soluble in water. This causes problems of dissolution profile and bioavailability. In the present invention, some studies have been done so that these problems do not appear.
It was seen that Tolvaptan Amorphous is better solubility than Tolvaptan Crystalline. In addition to solubility in the pharmaceutical composition, stability is also very important. It is very important for its stability that amorphous tolvaptan can be produced without turning into crystals and that it remains amorphous throughout its shelf life. To achieve this, it is found that for a tablet comprising amorphous tolvaptan, using wet granulation method with water is used and both the desired dissolution profile and stability is achieved. As used herein, the term "intragranular composition" refers to a population of granules that are wetted with solvent and then dried and granulated. Intragranular composition can be called also "granulate" or "granulate component". The "extragranular composition" refers is the part that does not participate in wet granulation.
According to this embodiment of the present invention, a tablet comprises an intragranular composition comprising amorphous tolvaptan and at least one binder, wherein the intragranular composition obtained by wet-granulation using water. These properties provide the desired dissolution profile and stability. Also, these provide the desired hardness and compressibility.
When amorphous tolvaptan treated with water, transition from amorphous to crystalline has not been observed. We found that when using else a solvent (for example ethyl alcohol and water mixture) during process, transition from amorphous form to crystalline form is seen.
Also, tolvaptan is used small proportion that can lead to considerable problems during the manufacture of the composition with regard to the uniformity of the content of active agent in the individual composition units. Because of problems uniformity of the content, the active substance may interact with several excipients. It reflects that content uniformity play important role in the dissolution of the drug. In this invention, to eliminate this problem, wet granulation is preferred in terms of pharmacotechnical properties, such as flowability, compressibility and content uniformity of tolvaptan.
Suitable binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, starch, pregelatinized starch, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, polymethacrylates, methacrylate polymers, hyaluronic acid, pectin, polysaccharides, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
The viscosity of a binder is a measure of its flow characteristics, and the performance of a bituminous mix is greatly affected by its viscosity. In the present invention, binders having low viscosity are used.
According to one embodiment of the present invention, the binder is polyvinylpyrrolidone. Polymer having low viscosity is povidone with a dynamic viscosity of 10% aqueous solution at 25°C up to about 10 mPa.s. Povidone is selected from the consisting of K12, K17, K25,K30, VA 64 and mixture thereof, more preferably VA 64. We saw that the use of the binder surprisingly achieved content uniformity, the desired flowabilirty and homogeneity of active agent. According to one embodiment of this invention, the amount of binder is between 1.0% and 20.0%, between 1.0% and 15.0% by weight of the total composition.
According to one embodiment of this invention, the amount of binder is between 3.0% and 10.0% by weight of the total composition.
According to one embodiment of this invention, the amount of amorphous tolvaptan is between 5.0% and 25.0%, between 8.0% and 25.0%, between 10.0% and 20.0% by weight of the total composition.
We have found that amorphous tolvaptan having the following particle sizes is important for formulation. Too small particle sizes influence the manufacturability, for example by sticking or filming. On the other hand too large particles negatively affect the dissolution properties of the pharmaceutical composition and dosage form and thus the bioavailability. In the following preferred ranges of the particle size distribution are described.
As used here in, "particle size distribution" is defined by the cumulative volume size distribution as tested by a conventionally accepted method which is the laser diffraction method determined by the equipment of Malvern Mastersizer 2000 laser diffraction particle size analyzer analyzer. "D (0.9)" or "d90" means that the size at which %90 by volume of the particles are finer, d (0.1) means that the size at which 10% by volume of the particles are finer and d (0.5) means that the size at which 50% by volume of the particles are finer. In this invention, particle size distribution of d (0.9) or d (0.5) or D(0.1) value of tolvaptan has been measured with solid samples and these values have been identified by Malvern Mastersizer 2000 laser diffraction particle size analyzer.
According to this embodiment of the present invention, amorphous tolvaptan has a d (0.9) particle size between 2 pm and 100 pm or between 3 pm and 50 pm or between 3 pm and 30 pm.
According to this embodiment of the present invention, amorphous tolvaptan has a d (0.9) particle size between 3 pm and 30 pm or between 3 pm and 25 pm or between 3 pm and 20 pm.
According to this embodiment of the present invention, amorphous tolvaptan has a d (0.5) particle size between 1 pm and 25 pm or between 1 pm and 15 pm or between 1 pm and 8 pm.
According to this embodiment of the present invention, amorphous tolvaptan has a d (0.5) particle size between 1 pm and 5 pm. According to this embodiment of the present invention, amorphous tolvaptan has a d (0.1) particle size between 0.1 pm and 20 pm or between 0.1 pm and 12 pm or between 0.1 pm and 8 pm.
According to this embodiment of the present invention, amorphous tolvaptan has a d (0.9) particle size between 2 pm and 100 pm, amorphous tolvaptan has a d (0.5) particle size between 1 pm and 30 pm, amorphous tolvaptan has a d (0.1) particle size between 0.1 pm and 12 pm. These particle size of amorphous tolvaptan helps to provide the desired dissolution profile by dissolving tolvaptan.
According to this embodiment of the present invention, a tablet comprises an intragranular composition comprising amorphous tolvaptan having a d (0.9) particle size between 2 pm and 100 pm and polyvinylpyrrolidone, wherein the intragranular composition is obtained by wet-granulation using water.
According to one embodiment of the present invention, an intragranular composition further comprises at least one pharmaceutically acceptable excipient selected from the group comprising disintegrants, fillers or mixtures thereof.
Suitable disintegrants are selected from the group comprising croscarmellose sodium, corn starch, starch, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, hydroxymethyl starch or mixtures thereof.
According to one embodiment of the present invention, the disintegrant is croscarmellose sodium.
According to one embodiment of this invention, the amount of disintegrant is between 1.0% and 20.0%, preferably between 3.0% and 15.0%, more preferably between 3.0% and 10.0% by weight of the total composition.
Suitable fillers are selected from the group comprising microcrystalline cellulose, lactose monohydrate, ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, compressible sugar, ethylcellulose, fructose, glyceryl palmitostearate, lactitol, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, sorbitol, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, xylitol or mixtures thereof.
According to one embodiment of the present invention, the filler is microcrystalline cellulose or lactose monohydrate or mixtures thereof. According to one embodiment of this invention, the amount of filler is between 55.0% and 90.0%, between 60.0% and 80.0% by weight of the total composition.
According to one embodiment of this invention, the tablet further comprises an extragranular composition comprising at least one pharmaceutically acceptable excipient selected from the group comprising coloring agents, lubricants or mixtures thereof.
Suitable coloring agents are selected from the group comprising indigo carmin aliminium lake, ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), poncau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
According to one embodiment of the present invention, the coloring agent is indigo carmin aliminium lake. This excipient is known as redox indicator. It prevents the active substance from being degraded by giving its own reversible reaction against oxidative and reducing substances (stress factors). Since the reaction is reversible, it is not completely depleted by its own degradation, and the raw material is protected from stress factors (oxidative and reducing species). This contributes positively to the shelf life of the product. This coloring agent provides the desired stability.
According to one embodiment of the present invention, the tablet comprises;
— Amorphous tolvaptan
— Croscarmellose sodium
— Polyvinylpyrrolidone VA 64
— Lactose Monohydrate
— Microcrystalline cellulose
— Indigo carmin aliminium lake
Suitable lubricants are selected from the group comprising magnesium stearate, calcium stearate, sodium stearyl fumarate, potassium stearate, stearic acid, sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols or mixtures thereof.
According to one embodiment of the present invention, the lubricant is magnesium stearate.
According to this embodiment of the invention, a process for preparing a tablet comprises the following steps: a) Dissolving polyvinylpyrrolidone VA 64 in water, b) Mixing amorphous tolvaptan, at least one disintegrant and at least one filler, c) Granulating the dry mixture at step (b) with the mixture step (a) and obtained wet granule, d) Drying the wet granule and then sieving, e) Adding indigo carmin aliminium lake and then mixing, f) Adding at least one lubricant and then mixing, g) Compressing the mixture into tablets.
According to this embodiment of the invention, a process for preparing a tablet comprises the following steps: a) Dissolving polyvinylpyrrolidone VA 64 in water, b) Mixing amorphous tolvaptan, lactose monohydrate, croscarmellose sodium and microcystralline cellulose, c) Granulating the dry mixture at step (b) with the mixture step (a) and obtained wet granule, d) Drying the wet granule and then sieving, e) Adding indigo carmin aliminium lake and then mixing, f) Adding magnesium stearate and then mixing, g) Compressing the mixture into tablets.
Example 1:
Figure imgf000008_0001
Example 2:
Figure imgf000009_0001
A process for example 1 or 2; a) Dissolving polyvinylpyrrolidone VA 64 in water, b) Mixing amorphous tolvaptan, lactose monohydrate, croscarmellose sodium and microcystralline cellulose, c) Granulating the dry mixture at step (b) with the mixture step (a) and obtained wet granule, d) Drying the wet granule and then sieving, e) Adding indigo carmin aliminium lake and then mixing, f) Adding magnesium stearate and then mixing, g) Compressing the mixture into tablets.

Claims

1) A tablet comprises an intragranular composition comprising amorphous tolvaptan and at least one binder, wherein the intragranular composition obtained by wet-granulation using water.
2) The tablet according to claim 1, wherein binders are selected from the group comprising polyvinylpyrrolidone, sodium carboxymethyl cellulose, sodium carboxymethyl cellulose, polyethylene glycol, starch, pregelatinized starch, sodium alginate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose, polymethacrylates, methacrylate polymers, hyaluronic acid, pectin, polysaccharides, polyacrylamide, polyoxyethylene-alkyl ether, polydextrose, polyethylene oxide or mixtures thereof.
3) The tablet according to claim 2, wherein the binder is polyvinylpyrrolidone.
4) The tablet according to claim 1, wherein amorphous tolvaptan has a d (0.9) particle size between 2 pm and 100 pm or between 3 pm and 50 pm or between 3 pm and 30 pm.
5) The tablet according to claim 1, wherein amorphous tolvaptan has a d (0.5) particle size between 1 pm and 25 pm or between 1 pm and 15 pm or between 1 pm and 8 pm.
6) The tablet according to claim 1, wherein amorphous tolvaptan has a d (0.1) particle size between 0.1 pm and 20 pm or between 0.1 pm and 12 pm or between 0.1 pm and 8 pm.
7) The tablet according to claim 1, wherein an intragranular composition further comprises at least one pharmaceutically acceptable excipient selected from the group comprising disintegrants, fillers or mixtures thereof.
8) The tablet according to claim 7, wherein disintegrants are selected from the group comprising croscarmellose sodium, corn starch, starch, low-substituted hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, hydroxymethyl starch or mixtures thereof.
9) The tablet according to claim 7, wherein fillers are selected from the group comprising microcrystalline cellulose, lactose monohydrate, ammonium alginate, calcium carbonate, calcium phosphate, calcium phosphate dehydrate, neutral pellets, calcium sulfate, cellulose, cellulose acetate, compressible sugar, ethylcellulose, fructose, glyceryl palmitostearate, lactitol, lactose, mannitol, magnesium carbonate, magnesium oxide, maltodextrin, maltose, medium chain triglycerides, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, sorbitol, sucrose, sugar spheres, sulfobutylether beta-cyclodextrin, talc, tragacanth, trehalose, xylitol or mixtures thereof.
10) The tablet according to claim 9, wherein the filler is microcrystalline cellulose or lactose monohydrate or mixtures thereof.
11) The tablet according to claim 1, wherein further comprises an extragranular composition comprising at least one pharmaceutically acceptable excipient selected from the group comprising coloring agents, lubricants or mixtures thereof.
12) The tablet according to claim 11, wherein the coloring agent is indigo carmin aliminium lake.
13) The tablet according to claim 11, wherein lubricants are selected from the group comprising magnesium stearate, calcium stearate, sodium stearyl fumarate, potassium stearate, stearic acid, sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols or mixtures thereof.
14) The tablet according to claim 1, wherein the tablet comprises;
— Amorphous tolvaptan
— Croscarmellose sodium
— Polyvinylpyrrolidone VA 64
— Lactose Monohydrate
— Microcrystalline cellulose
— Indigo carmin aliminium lake
15) A process for preparing a tablet comprises the following steps: a) Dissolving polyvinylpyrrolidone VA 64 in water, b) Mixing amorphous tolvaptan, at least one disintegrant and at least one filler, c) Granulating the dry mixture at step (b) with the mixture step (a) and obtained wet granule, d) Drying the wet granule and then sieving, e) Adding indigo carmin aliminium lake and then mixing, f) Adding at least one lubricant and then mixing, g) Compressing the mixture into tablets.
PCT/TR2023/050146 2022-02-18 2023-02-15 A tablet of tolvaptan and at least one binder processed with wet granulation WO2023158411A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2022002172 2022-02-18
TR2022/002172 2022-02-18
TR2022/006273 2022-04-20
TR2022006273 2022-04-20

Publications (1)

Publication Number Publication Date
WO2023158411A1 true WO2023158411A1 (en) 2023-08-24

Family

ID=87578899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2023/050146 WO2023158411A1 (en) 2022-02-18 2023-02-15 A tablet of tolvaptan and at least one binder processed with wet granulation

Country Status (1)

Country Link
WO (1) WO2023158411A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165249A1 (en) * 2008-09-05 2011-07-07 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical solid preparation
CN102512393A (en) * 2011-12-19 2012-06-27 浙江华海药业股份有限公司 Oral disintegrated tablet containing tolvaptan

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165249A1 (en) * 2008-09-05 2011-07-07 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical solid preparation
CN102512393A (en) * 2011-12-19 2012-06-27 浙江华海药业股份有限公司 Oral disintegrated tablet containing tolvaptan

Similar Documents

Publication Publication Date Title
RU2181590C2 (en) Irbesartan-containing pharmaceutical compositions
WO2020249001A1 (en) Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
KR101815722B1 (en) Tolvaptan solid dispersion and its preparation method
KR20180109992A (en) A pharmaceutical composition comprising a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof
JP6895779B2 (en) Azilsartan-containing solid pharmaceutical composition
EP1793801A1 (en) Novel granulation process and granulate produced therefrom
EP2595607A2 (en) Medicinal drug for oral administration comprising a mixture of silodosin and a basic copolymer
EP2197428A1 (en) Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
EP2203156A2 (en) Candesartan cilexetil
WO2006123213A1 (en) Modified release formulations of gliclazide
JPH08310969A (en) Solid pharmaceutical composition and its preparation
WO2023158411A1 (en) A tablet of tolvaptan and at least one binder processed with wet granulation
EP2946771B1 (en) Water-dispersible tablet formulation comprising deferasirox
JPH04159222A (en) Production of solid preparation for oral administration
US20110223245A1 (en) Controlled-release formulations of pramipexole
WO2024030098A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation
JP2000516601A (en) Granules containing water-soluble compounds and cellulose
WO2020122244A1 (en) Tablet and method for producing same
EP2471520B1 (en) Pharmaceutical compositions of levetiracetam
EP4321154A1 (en) A tablet of tolvaptan and at least one binder processed with spray granulation
AU2016217658B2 (en) Method of producing a granulated composition
CN109864971B (en) Granules of lamotrigine solid dispersion and preparation method thereof
EP3928771A1 (en) Pharmaceutical compositions of 1,2-benzisoxazole-3-methanesulfonamide
WO2022119543A1 (en) A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
RU2696870C2 (en) Oral preparation with sustained release

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23756751

Country of ref document: EP

Kind code of ref document: A1